Revance Specifies 2016 Clinical Program Milestones
January 07, 2016 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
December 23, 2015 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Appoints Abhay Joshi, PhD, as Chief Operating Officer
December 14, 2015 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics to Participate in the 27th Annual Piper Jaffray Healthcare Conference
November 19, 2015 16:03 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Releases Third Quarter 2015 Results
November 09, 2015 16:03 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Announces Closing of Public Offering of Common Stock
November 09, 2015 12:10 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the closing of its underwritten public offering of 3,737,500 shares of its common stock at a...
Revance Therapeutics to Present at Credit Suisse 24th Annual Healthcare Conference
November 04, 2015 16:24 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics to Release Third Quarter 2015 Financial Results Monday, November 9, 2015
November 04, 2015 16:20 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Announces Pricing of Public Offering of Common Stock
November 04, 2015 00:20 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 3,250,000 shares of its common stock at a...
Revance Therapeutics Announces Proposed Public Offering of Common Stock
November 02, 2015 06:02 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,250,000 shares of its common stock. Revance...